Marina Shcherba

2.4k total citations
22 papers, 273 citations indexed

About

Marina Shcherba is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Marina Shcherba has authored 22 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Marina Shcherba's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Esophageal Cancer Research and Treatment (4 papers). Marina Shcherba is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Esophageal Cancer Research and Treatment (4 papers). Marina Shcherba collaborates with scholars based in United States and Canada. Marina Shcherba's co-authors include Haiying Cheng, Román Pérez-Soler, Yuanxin Liang, Bilal Piperdi, Gopichand Pendurti, Missak Haigentz, Yelena Y. Janjigian, David H. Ilson, Jonathan Shuter and Geoffrey Y. Ku and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of General Internal Medicine.

In The Last Decade

Marina Shcherba

19 papers receiving 269 citations

Peers

Marina Shcherba

ONCOL

PRM

SURGE

Maria Grazia Rodriquenz Italy

Itsuro Terada Japan

Shinji Endo Japan

Mariko Asano Japan

Hideo Tomioka Japan

Matthias PA Ebert Germany

Liangshuo Hu China

Masaki Tateishi Japan

Masaki Tsujie Japan

Wenhui Wu China

Maria Grazia Rodriquenz Italy

Marina Shcherba

149 ×1.1

ONCOL

97 ×1.0

PRM

77 ×0.8

62 ×1.2

SURGE

51 ×1.4

Citations per year, relative to Marina Shcherba Marina Shcherba (= 1×) peers Maria Grazia Rodriquenz

Countries citing papers authored by Marina Shcherba

Since Specialization

Citations

This map shows the geographic impact of Marina Shcherba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Shcherba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Shcherba more than expected).

Fields of papers citing papers by Marina Shcherba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Shcherba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Shcherba. The network helps show where Marina Shcherba may publish in the future.

Co-authorship network of co-authors of Marina Shcherba

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Shcherba. A scholar is included among the top collaborators of Marina Shcherba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Shcherba. Marina Shcherba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lumish, Melissa, Jenna Sinopoli, Zsofia K. Stadler, et al.. (2022). PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.. Journal of Clinical Oncology. 40(4_suppl). 16–16. 12 indexed citations

Wu, Abraham J., Smita Sihag, Henry Walch, et al.. (2022). Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.. Journal of Clinical Oncology. 40(16_suppl). 4029–4029. 5 indexed citations

Moy, Ryan H., Steven B. Maron, Marina Shcherba, et al.. (2021). A nutritional management algorithm in older patients with locally advanced esophageal cancer.. Journal of Clinical Oncology. 39(15_suppl). e16038–e16038.

Ku, Geoffrey Y., Abraham J. Wu, Smita Sihag, et al.. (2021). Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.. Journal of Clinical Oncology. 39(3_suppl). 226–226. 5 indexed citations

Diplas, Bill H., Ryan Ptashkin, Andrea Cercek, et al.. (2021). Clinical relevance of clonal hematopoiesis in metastatic gastrointestinal malignancies.. Journal of Clinical Oncology. 39(15_suppl). e16082–e16082. 1 indexed citations

Janjigian, Yelena Y., Joanne F. Chou, Marc Simmons, et al.. (2019). First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).. Journal of Clinical Oncology. 37(4_suppl). 62–62. 44 indexed citations

Janjigian, Yelena Y., Steven B. Maron, Joanne F. Chou, et al.. (2019). First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma. Annals of Oncology. 30. v313–v313. 8 indexed citations

Janjigian, Yelena Y., Steven B. Maron, Joanne F. Chou, et al.. (2019). First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.. Journal of Clinical Oncology. 37(15_suppl). 4011–4011. 15 indexed citations

Ma, Jennifer, Benjamin H. Lok, Jingfeng Zong, et al.. (2018). Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. International Journal of Particle Therapy. 4(4). 10–19. 9 indexed citations

10.

Yu, Kenneth H., Simon Mantha, Robin Brenner, et al.. (2018). Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. Journal of Clinical Oncology. 36(4_suppl). 405–405. 3 indexed citations

11.

Shcherba, Marina, et al.. (2015). Liver Failure after Hydroxycut™ Use in a Patient with Undiagnosed Hereditary Coproporphyria. Journal of General Internal Medicine. 30(6). 856–859. 5 indexed citations

12.

Cheng, Haiying, et al.. (2015). Emerging drugs for squamous cell lung cancer. Expert Opinion on Emerging Drugs. 20(1). 149–160. 15 indexed citations

13.

Shcherba, Marina, et al.. (2014). Cell cycle inhibitors for the treatment of NSCLC. Expert Opinion on Pharmacotherapy. 15(7). 991–1004. 14 indexed citations

14.

Shcherba, Marina, H. Dean Hosgood, Juan Lin, et al.. (2014). Characteristics of HIV+ lung cancer cases in a large clinical population: Implications for lung cancer screening.. Journal of Clinical Oncology. 32(15_suppl). 1569–1569.

15.

Cheng, Haiying, Marina Shcherba, Gopichand Pendurti, et al.. (2014). Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. PubMed. 3(1). 67–75. 109 indexed citations

16.

Shcherba, Marina, V. Shankar, Dukagjin Blakaj, Madhur Garg, & Missak Haigentz. (2013). Treatment-associated mortality in head and neck cancer: Analysis of phase III trials.. Journal of Clinical Oncology. 31(15_suppl). 6064–6064. 1 indexed citations

17.

Shcherba, Marina, Jonathan Shuter, & Missak Haigentz. (2013). Current questions in HIV-associated lung cancer. Current Opinion in Oncology. 25(5). 511–517. 13 indexed citations

18.

Janakiram, Murali, et al.. (2013). A Systematic Review of the Utility of Residual Vein Obstruction Studies in Primary and Secondary Venous Thrombosis. PubMed. 2013. 1–9. 10 indexed citations

19.

Samsonov, G. V., et al.. (1979). [Reverse oxygenation and biological properties of high molecular weight modified hemoglobin].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 248(1). 254–6. 2 indexed citations

20.

Shcherba, Marina, et al.. (1976). Effect of hyperoxia on rate of restoration of the blood composition after blood loss. Bulletin of Experimental Biology and Medicine. 82(4). 1477–1479.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact